Lead Structure-Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal-Type Sirt2 Inhibitors.

Area of Science:

• Biochemistry
• Neuroscience
• Medicinal Chemistry

Background:

• Sirtuin 2 (Sirt2) inhibitors are crucial epigenetic targets for treating neurodegenerative diseases.
• Current Sirt2 inhibitors have limitations, necessitating the development of more potent and selective compounds.

Purpose of the Study:

• To design and synthesize novel, highly potent, and subtype-selective Sirt2 inhibitors.
• To explore structure-activity relationships (SAR) for next-generation Sirt2 inhibitors.

Main Methods:

• Structure-based drug design utilizing molecular docking and MM/GBSA validation.
• Lead structure hybridization strategy to create a new series of Sirt2 inhibitors.

Main Results:

• Identification of RW-93, a highly potent Sirt2 inhibitor with an IC50 of 16 nM.
• RW-93 demonstrates superior potency and selectivity compared to existing Sirt2 inhibitors.
• The study successfully extended the SAR profile for Sirt2 inhibitors.

Conclusions:

• RW-93 represents a significant advancement in Sirt2 inhibitor development.
• The findings provide a promising foundation for further medicinal chemistry efforts in treating neurodegenerative diseases.
• This research offers a potent low-molecular-weight Sirt2 inhibitor for future therapeutic strategies.